Janssen’s drug gets Board nod for Prostate Cancer treatment

ZYTIGA has also received international recognition as a broad indication treatment drug for prostate cancer. [Courtesy]

The Pharmacy and Poisons Board (PPB) has approved the use of the prescription drug, ZYTIGA, for the treatment of newly-diagnosed metastatic prostate cancer.

ZYTIGA also referred to as abiraterone acetate will now be used for the treatment of metastatic hormone-sensitive prostate cancer before a chemotherapy regime.